Second hematologic malignancies after ABVD: Two case reports and a retrospective study of 183 Hodgkin lymphoma patients.
Leong
Carrie
C
Department of Medical Oncology, National Cancer Centre, Singapore, Singapore. carrie_leong@hotmail.com
Ngeow
Joanne
J
Tan
Iain
I
Quek
Richard
R
Tao
Miriam
M
Loh
Yvonne
Y
Tan
Huey Ching
HC
Lim
Soon Thye
ST
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001761:Bleomycin / Q000009:adverse effects; D003606:Dacarbazine / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D014747:Vinblastine / Q000009:adverse effects
D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin